ConductScience.org, home

Paper30050331

A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.

Li Y and 7 others. Clin Pharmacol, 2018. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension. Papers, record 30050331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30050331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension.
PubMed
Journal
Clin Pharmacol
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.16
iCite
Revised in PubMed
2022-03-18
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li YYan
2Liu LLiangang
3Huang LLian
4Wang XXiaomin
5Hoffmann MMatthew
6Reyes JJosephine
7Palmisano MMaria
8Zhou SSimon

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123203815Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.Cancer Chemother Pharmacol2013https://conductscience.org/library/papers/23203815PubMed
217517289Recovery from postsurgical swallowing dysfunction in patients with oral cancer.J Oral Maxillofac Surg2007https://conductscience.org/library/papers/17517289PubMed
323961770Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Expert Opin Drug Metab Toxicol2013https://conductscience.org/library/papers/23961770PubMed
424421329Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.Blood2014https://conductscience.org/library/papers/24421329PubMed
511753617Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.Leukemia2001https://conductscience.org/library/papers/11753617PubMed
625047979Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.Leuk Res2014https://conductscience.org/library/papers/25047979PubMed
711049970Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood2000https://conductscience.org/library/papers/11049970PubMed
818805433The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.Microvasc Res2009https://conductscience.org/library/papers/18805433PubMed
91778094Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population.Dysphagia1991https://conductscience.org/library/papers/1778094PubMed
1012036884Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood2002https://conductscience.org/library/papers/12036884PubMed
1125556560Population pharmacokinetics of pomalidomide.J Clin Pharmacol2015https://conductscience.org/library/papers/25556560PubMed
1222205548Swallowing dysfunction in cancer patients.Support Care Cancer2012https://conductscience.org/library/papers/22205548PubMed
1312666243Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.Chirality2003https://conductscience.org/library/papers/12666243PubMed
1423944852An occupational therapy program for patients with swallowing dysfunction following cancer treatment.Occup Ther Health Care1986https://conductscience.org/library/papers/23944852PubMed
1515638853Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol2005https://conductscience.org/library/papers/15638853PubMed
1618392823Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.Cancer Immunol Immunother2008https://conductscience.org/library/papers/18392823PubMed
1724007748Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.Lancet Oncol2013https://conductscience.org/library/papers/24007748PubMed
1810384139Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.J Immunol1999https://conductscience.org/library/papers/10384139PubMed
1929670410Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib.Clin Pharmacol2018https://conductscience.org/library/papers/29670410PubMed
2024833703Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers.J Pharmacol Exp Ther2014https://conductscience.org/library/papers/24833703PubMed

See all 24 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42814376
Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking.
Clin Pharmacokinet2026https://conductscience.org/library/papers/42814376PubMed
36106110Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.Front Oncol2022https://conductscience.org/library/papers/36106110PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30050331

GET https://conductscience.org/api/papers/v1/30050331/references?page=2